Search for Cases

Case Details

Case Code: BSTR484
Case Length: 18 Pages 
Period: 2001-2015  
Pub Date: 2015
Teaching Note: NOT Available
Price:Rs.600
Organization : GlaxoSmithKline plc (GSK)
Industry :Pharmaceutical
Countries : UK
Themes: Radical openness
Case Studies  
Business Strategy
Marketing
Finance
Human Resource Management
IT and Systems
Operations
Economics
Leadership & Entrepreneurship

GSK Promoting Collaboration through Radical Openness

 

ABSTRACT

 

GlaxoSmithKline plc (GSK) is redefining the way pharmaceutical industry works. In an industry which is known for secrecy and non-transparency, GSK has taken to radically defining openness by adapting open innovation and opening its labs for collaborations. It is also sharing its clinical trials data and intellectual property in order to promote transparency and is hoping to discover drugs faster and save millions of people suffering from various diseases. On the other critics opined that this open strategy is a part of market segmentation strategy to cater to patients in both the developing countries and the developed countries. They say that there is no major difference to patients on the ground as the price of GSK’s products were still out of the pocket of millions residing in least developed countries...

 
Business Strategy Case Studies | Case Study in Management, Operations, Strategies, Business Environment, Case Studies
or
Business Strategy Case Studies | Case Study in Management, Operations, Strategies, Business Environment, Case Studies
or
PayPal (13 USD)

 

Issues

The case is structured to achieve the following teaching objectives:
  • Identify the driving forces behind radical Openness.
  • Understand the role played by Radical Openness in a secretive pharmaceutical industry
  • Identify the quantum of benefits that GSK realized as a result of Radical Openness
  • Debate on Radical Openness as a competitive Advantage
Contents
TOUGH TIME FOR ANDREW WITTY, CEO OF GSK
OVERVIEW OF PHARMACEUTICAL INDUSTRY
GROWTH DRIVERS
CHALLENGES
ABOUT GSK
RADICAL OPENNESS @ GSK
THE CRITICISM
THE OUTCOMES
NEXT LEVEL OF OPENNESS
EXHIBITS

Keywords

Radical Openness, Pharmaceutical industry, GSK, Transparency, Open Lab, Clinical trials, Intellectual property, Research and Development, Clinical Study Register, Harvard Medical School, Non-Communicable Diseases, HIV, Malaria, Cancer, Neglected Tropical Diseases

TOUGH TIME FOR ANDREW WITTY, CEO OF GSK- Next Page>>